# Tanai Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tanai-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Belgium
- Total disclosed funding: $3.1M
- Latest round: Seed (Sep 19, 2024)
- Investors on record: 5

## About

Based in Belgium, Tanai Therapeutics is a company developing a first-in-class, oral obesity drug. In September 2024, Tanai Therapeutics raised seed funding from Novo Nordisk A/S and BioGeneration Ventures, with participation from V-Bio Ventures, Qbic, and VIB.

Tanai Therapeutics is a biotechnology company focused on developing a novel oral therapeutic for obesity. The company's approach targets a genetically validated pathway involved in energy expenditure, aiming to promote fat loss while preserving muscle mass. The company’s research is based on work conducted at the VIB-UGent Center for Inflammation Research, and it is advancing toward in-vivo proof-of-concept. 

The company intends to use the September 2024 funding to develop oral therapeutics for obesity.

## Funding rounds

- Seed, Sep 19, 2024 — BioGeneration Ventures, Novo Nordisk A/S, VIB, Qbic Fund, V-Bio Ventures
- Seed, Dec 6, 2023, $3.1M — VIB, Qbic Fund, V-Bio Ventures

## Investors

- VIB — Seed
- Qbic Fund (https://capitalatlas.ai/funds/qbic-fund) — Seed
- V-Bio Ventures (https://capitalatlas.ai/funds/v-bio-ventures) — Seed
- BioGeneration Ventures (https://capitalatlas.ai/funds/biogeneration-ventures) — Seed
- Novo Nordisk A/S — Seed